UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000058700
Receipt number R000067108
Scientific Title A double-blind trial examining the effect of lactic acid bacteria on N1487-7 lowering cholesterol levels: placebo-controlled, double-blind, randomized parallel comparative test
Date of disclosure of the study information 2025/08/20
Last modified on 2025/08/04 15:15:56

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A double-blind trial examining the effect of lactic acid bacteria on N1487-7 lowering cholesterol levels

Acronym

A double-blind trial examining the effect of lactic acid bacteria on N1487-7 lowering cholesterol levels

Scientific Title

A double-blind trial examining the effect of lactic acid bacteria on N1487-7 lowering cholesterol levels:
placebo-controlled, double-blind, randomized parallel comparative test

Scientific Title:Acronym

A double-blind trial examining the effect of lactic acid bacteria on N1487-7 lowering cholesterol levels:
placebo-controlled, double-blind, randomized parallel comparative test

Region

Japan


Condition

Condition

Healthy individuals

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effect on lowering cholesterol levels of ingestion of test food for 12 consecutive weeks, using placebo as a control.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

LDL cholesterol
HDL cholesterol
Total cholesterol

Key secondary outcomes

Oxidized LDL cholesterol
sd-LDL cholesterol
RLP cholesterol
non-HDL cholesterol
IL-10


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake of test food for 12 consecutive weeks

Interventions/Control_2

Intake of control placebo for 12 consecutive weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Healthy males and females from 20 to 64 years old
(2) Participants with LDL cholesterol levels of 120-139 mg/dL or 140-159 mg/dL. However, less than half of the participants should have140-159 mg/dL.
(3) Participants who received sufficient explanation about the purpose and content of the test, had the ability to consent, voluntarily volunteered to participate after understanding it well, and agreed to participate in the test in writing.

Key exclusion criteria

(1) Participants with a history of hypercholesterolemia, psychiatric disorders, diabetes, liver disease, kidney disease, digestive disorders, cardiac diseases, respiratory diseases, peripheral vascular disorders, or other serious diseases
(2) Participants who undergo surgery on the digestive tract
(3) Participants with abnormal liver and kidney function tests
(4) Participants with diseases currently being treated
(5) Participants who are allergic to food and drugs
(6) Participants with anemia symptoms
(7) Female participants wishing to become pregnant while participating in this study, pregnant (including those who may be pregnant) or lactating female participants
(8) Participants who play intense sports and participants who are on a diet
(9) Participants with extremely irregular eating habits
(10) Participants who cannot stop taking health foods (including foods for specified health use and foods with functional claims) and quasi-drugs during the test period
(11) Participants who are continuously receiving treatment with pharmaceuticals (including OTC and prescription drugs)
(12) Participants who drink more than 60 g of average daily pure alcohol
(13) Participants who smoke an average of 21 or more cigarettes a day
(14) Participants who are participating in or will participate in other clinical trials at the start of this study.
(15) Other participants judged by the investigator or the investigator to be inappropriate for the examination

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Naoki
Middle name
Last name Miura

Organization

Miura Clinic, Medical Corporation Kanonkai

Division name

Internal medicine

Zip code

5300044

Address

Higashitenma building 9F, 1-7-17, Higashitenma, Kita-ku, Osaka

TEL

06-6135-5200

Email

info@miura-cl.jp


Public contact

Name of contact person

1st name Makoto
Middle name
Last name Terashima

Organization

Oneness Support Co., Ltd.

Division name

Clinical Trial Division

Zip code

5300044

Address

Higashitenma building 6F, 1-7-17, Higashitenma, Kita-ku, Osaka

TEL

06-4801-8917

Homepage URL


Email

mterashima@oneness-sup.co.jp


Sponsor or person

Institute

Miura Clinic, Medical Corporation Kanonkai

Institute

Department

Personal name



Funding Source

Organization

Sanwa Shurui Co.,ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Ethics Committee of Miura Clinic, Medical Corporation Kanonkai

Address

Higashitenma building 9F, 1-7-17, Higashitenma, Kita-ku, Osaka

Tel

06-6135-5200

Email

mterashima@miura-cl.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人花音会みうらクリニック(大阪府)


Other administrative information

Date of disclosure of the study information

2025 Year 08 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2025 Year 07 Month 23 Day

Date of IRB

2025 Year 07 Month 30 Day

Anticipated trial start date

2025 Year 09 Month 11 Day

Last follow-up date

2025 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2025 Year 08 Month 05 Day

Last modified on

2025 Year 08 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067108